Txcell SA, of Valbonne, France, presented preclinical data at the Congress of the European Society for Organ Transplantation meeting in Barcelona, Spain, describing results with its second-generation CAR-Tregs (HLA-A2 CAR-Tregs) in a graft-vs.-host disease (GvHD) model.